Last reviewed · How we verify
LMWH and Phenprocoumon
At a glance
| Generic name | LMWH and Phenprocoumon |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
- Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
- D-Dimer Guided Oral Anticoagulant Treatment (OAT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMWH and Phenprocoumon CI brief — competitive landscape report
- LMWH and Phenprocoumon updates RSS · CI watch RSS
- Bayer portfolio CI